Bexion Pharmaceuticals, Inc. Awarded Grant from The Michael J. Fox Foundation to Advance BXQ-350
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...
Light-based therapy reduces pain associated with peripheral diabetic neuropathy, study concludes
A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Le Lézard4d
Bexion Pharmaceuticals, Inc. to Participate in the Jefferies London Healthcare Conference
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...
oncnursingnews5d
Topical Drug Combos May Be Beneficial for CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
Neuropathy is becoming a bigger problem for more people than ever before
If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...
manilatimes5d
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
we received FDA clearance to begin trials in chemotherapy-induced peripheral neuropathy. This debilitating condition, for ...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
The Bakersfield Californian6d
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
In May 2024, Zai Lab announced that the Centre for Drug Evaluation (CDE) accepted the sBLA with priority review designation for VYVGART Hytrulo for CIDP in China. The CDE granted the Breakthrough ...